Form 4: Bionano Genomics Director Christopher J. Twomey Granted Stock Options

Bionano Genomics, Inc. Director Christopher J. Twomey was granted 2,775 stock options with an exercise price of $3.67, vesting over 12 months.

Summary

• Christopher J. Twomey, a Director of Bionano Genomics, Inc. (BNGO), was granted 2,775 stock options.
• The transaction date for the grant was June 11, 2025.
• The exercise price for these stock options is $3.67 per share.
• The options will vest in equal monthly installments over the 12 months following the grant date.
• The options will be fully vested on the date of the Company's next annual stockholder meeting, subject to continuous service.
• Full vesting will also occur upon a Change of Control, as defined in the Company's 2018 equity incentive plan.
• The expiration date for these stock options is June 10, 2035.
• Following this transaction, Christopher J. Twomey beneficially owns 2,775 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event, not a significant operational or financial announcement.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• This is a standard form of compensation for directors, indicating ongoing commitment and engagement from the board.

Future Outlook

The granted stock options are subject to a vesting schedule over the next 12 months, or until the next annual stockholder meeting, provided the director maintains continuous service. Full vesting would also occur upon a change of control.

Industry Context

The grant of stock options to a director is a common practice in publicly traded companies across various industries, serving as a key component of executive and director compensation packages designed to align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice, comparable to similar arrangements at other biotechnology or life sciences companies.
• The vesting schedule (monthly over 12 months or upon next annual meeting) is a typical structure for director equity awards, aiming to retain talent and ensure long-term commitment.

Related Party Transactions

• The grant of stock options to Christopher J. Twomey, a Director of Bionano Genomics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options can lead to potential future dilution if exercised, but also aims to align the director's long-term interests with shareholder value creation.
• Employees: While not directly impacting all employees, such grants are part of the company's overall equity incentive framework, which can influence broader compensation strategies.

Next Steps

• The stock options will begin vesting in equal monthly installments over the 12 months following the grant date of June 11, 2025.
• The options will fully vest on the date of the Company's next annual stockholder meeting, subject to continuous service.

Key Dates

Keywords

Bionano Genomics, BNGO, Stock Options, Insider Transaction, Director Compensation, Form 4, Equity Incentive Plan